A new and superior adrenal scanning agent, NP-59.
The first synthesis of 131I-19-iodocholesterol had a 10-25% radiochemical impurity that was not iodide ion. This impurity has been identified as 6beta-131I-iodomethyl-19-nor cholest 5(10)-en-3beta-ol (NP-59) and has been synthesized. Tissue distribution studies with 131I-NP-59 in rats and dogs revealed a higher adrenal uptake and adrenal-to-tissue ratios compared to 131I-19-iodocholesterol, probably less in vivo deiodination, and superior adrenal images. A high uptake was seen in the adrenal medulla in addition to that in the cortex. Iodine-131-NP-59 is being evaluated for the early detection of adrenal-cortical disorders and as a potential scanning agent for detecting structural abnormalities of the adrenal medulla.
D000307:Adrenal Gland Diseases / Q000175:diagnosis*; D000818:Animals; D002782:Cholestenes; D002784:Cholesterol / Q000031:analogs & derivatives; D004285:Dogs; D005260:Female; D007457:Iodine Radioisotopes; D011877:Radionuclide Imaging; D051381:Rats
D002782:Cholestenes; D007457:Iodine Radioisotopes; D002784:Cholesterol